111 related articles for article (PubMed ID: 11036198)
21. Differential effects of bupivacaine enantiomers, ropivacaine and lidocaine on up-regulation of cell surface voltage-dependent sodium channels in adrenal chromaffin cells.
Shiraishi S; Yokoo H; Yanagita T; Kobayashi H; Minami S; Saitoh T; Takasaki M; Wada A
Brain Res; 2003 Mar; 966(2):175-84. PubMed ID: 12618341
[TBL] [Abstract][Full Text] [Related]
22. Intracellular distribution of a cytoplasmic progesterone receptor mutant and of immunophilins cyclophilin 40 and FKBP59: effects of cyclosporin A, of various metabolic inhibitors and of several culture conditions.
Lebeau MC; Jung-Testas I; Baulieu EE
J Steroid Biochem Mol Biol; 1999; 70(4-6):219-28. PubMed ID: 10622411
[TBL] [Abstract][Full Text] [Related]
23. Prolyl isomerases in yeast.
Arevalo-Rodriguez M; Wu X; Hanes SD; Heitman J
Front Biosci; 2004 Sep; 9():2420-46. PubMed ID: 15353296
[TBL] [Abstract][Full Text] [Related]
24. Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel.
Fuhrer DK; Kobayashi M; Jiang H
Diabetes Obes Metab; 2001 Dec; 3(6):393-402. PubMed ID: 11903410
[TBL] [Abstract][Full Text] [Related]
25. FK506 induces chondrogenic differentiation of clonal mouse embryonic carcinoma cells, ATDC5.
Nishigaki F; Sakuma S; Ogawa T; Miyata S; Ohkubo T; Goto T
Eur J Pharmacol; 2002 Feb; 437(3):123-8. PubMed ID: 11890899
[TBL] [Abstract][Full Text] [Related]
26. Time-dependent inhibition of peptidylprolyl cis-trans-isomerases by FK506 is probably due to cis-trans isomerization of the inhibitor's imide bond.
Zarnt T; Lang K; Burtscher H; Fischer G
Biochem J; 1995 Jan; 305 ( Pt 1)(Pt 1):159-64. PubMed ID: 7529995
[TBL] [Abstract][Full Text] [Related]
27. Glycogen synthase kinase-3beta: homologous regulation of cell surface insulin receptor level via controlling insulin receptor mRNA stability in adrenal chromaffin cells.
Yokoo H; Nemoto T; Yanagita T; Satoh S; Yoshikawa N; Maruta T; Wada A
J Neurochem; 2007 Dec; 103(5):1883-96. PubMed ID: 17883398
[TBL] [Abstract][Full Text] [Related]
28. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction.
Sigal NH; Dumont FJ
Annu Rev Immunol; 1992; 10():519-60. PubMed ID: 1375473
[TBL] [Abstract][Full Text] [Related]
29. Cyclosporins: lack of correlation between antischistosomal properties and inhibition of cyclophilin isomerase activity.
Khattab A; Pica-Mattoccia L; Klinkert MQ; Wenger R; Cioli D
Exp Parasitol; 1998 Sep; 90(1):103-9. PubMed ID: 9709036
[TBL] [Abstract][Full Text] [Related]
30. Distinct regulation of insulin receptor substrate-1 and -2 by 90-kDa heat-shock protein in adrenal chromaffin cells.
Yoshikawa N; Nemoto T; Satoh S; Maruta T; Yanagita T; Chosa E; Wada A
Neurochem Int; 2010 Jan; 56(1):42-50. PubMed ID: 19737590
[TBL] [Abstract][Full Text] [Related]
31. The immunosuppressive agents rapamycin, cyclosporin A and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid metabolism in human adipose tissue.
Pereira MJ; Palming J; Rizell M; Aureliano M; Carvalho E; Svensson MK; Eriksson JW
Mol Cell Endocrinol; 2013 Jan; 365(2):260-9. PubMed ID: 23160140
[TBL] [Abstract][Full Text] [Related]
32. Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling.
Hafizi S; Mordi VN; Andersson KM; Chester AH; Yacoub MH
Vascul Pharmacol; 2004; 41(4-5):167-76. PubMed ID: 15607500
[TBL] [Abstract][Full Text] [Related]
33. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation.
Hess DA; Bird IA; Almawi WY; Rieder MJ
J Pharmacol Exp Ther; 1997 Apr; 281(1):540-8. PubMed ID: 9103542
[TBL] [Abstract][Full Text] [Related]
34. Effects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12.
Kaye RE; Fruman DA; Bierer BE; Albers MW; Zydowsky LD; Ho SI; Jin YJ; Castells MC; Schreiber SL; Walsh CT
Proc Natl Acad Sci U S A; 1992 Sep; 89(18):8542-6. PubMed ID: 1382293
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of endogenous MHC class II-restricted antigen presentation by tacrolimus (FK506) via FKBP51.
Imai A; Sahara H; Tamura Y; Jimbow K; Saito T; Ezoe K; Yotsuyanagi T; Sato N
Eur J Immunol; 2007 Jul; 37(7):1730-8. PubMed ID: 17523132
[TBL] [Abstract][Full Text] [Related]
36. The immunosuppressant rapamycin, alone or with transforming growth factor-beta, enhances osteoclast differentiation of RAW264.7 monocyte-macrophage cells in the presence of RANK-ligand.
Shui C; Riggs BL; Khosla S
Calcif Tissue Int; 2002 Nov; 71(5):437-46. PubMed ID: 12202955
[TBL] [Abstract][Full Text] [Related]
37. Nephrotoxicity of immunosuppressants in rats: comparison of macrolides with cyclosporin.
Ryffel B; Weber E; Mihatsch MJ
Exp Nephrol; 1994; 2(6):324-33. PubMed ID: 7532090
[TBL] [Abstract][Full Text] [Related]
38. Cyclosporin a inhibits calcineurin/nuclear factor of activated T-cells signaling and induces apoptosis in retinoblastoma cells.
Eckstein LA; Van Quill KR; Bui SK; Uusitalo MS; O'Brien JM
Invest Ophthalmol Vis Sci; 2005 Mar; 46(3):782-90. PubMed ID: 15728531
[TBL] [Abstract][Full Text] [Related]
39. Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.
Nielsen FT; Ottosen P; Starklint H; Dieperink H
Nephrol Dial Transplant; 2003 Mar; 18(3):491-6. PubMed ID: 12584269
[TBL] [Abstract][Full Text] [Related]
40. Effect of cyclosporin and tacrolimus (FK506) on the antigen-induced mediator release, membrane potential and 86Rb+/K+ and Ca2+ fluxes in the RBL-2H3 cell line.
Narenjkar J; Assem el-SK; Wan BY; Marsh S; Ezeamuzie CI
Int Immunopharmacol; 2006 May; 6(5):742-9. PubMed ID: 16546704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
